Work begins on Noumed’s $100 Million Adelaide pharmaceutical manufacturing plant

Noumed Pharmaceutical’s investment in the health of Australians took a leap forward  with a sod-turning ceremony on the site of its future manufacturing plant that will boost Australia’s access to key medicines and create hundreds of jobs by 2026.
The $100 Million project, which will receive up to $20 million in Australian Government funding, will enhance Australia’s sovereign supply into the pharmacy and health network by bringing the manufacture of millions of units of important everyday medicines onshore.
The site on which the plant is being built measures 43,000m2   – about 2.5 times the size of Adelaide Oval. The state-of-the-art manufacturing facility will be approximately 26,000m2   and is being built in the Terre Property Partners Nexus North Industrial Estate in Salisbury, north of Adelaide. EY M&A Adelaide has also been engaged to source a minority capital investment for the final stages of the facility’s funding.
Noumed’s Managing Director, Mark Thulborne, said this is an exciting time for Noumed, as the plant will be one of the most modern and efficient of its type in the Southern Hemisphere. “Noumed is excited to reach this project milestone towards our goal to bring manufacturing back into Australia.
“This is good news for the continuity of effective, affordable healthcare in our country. The global pandemic highlighted the value of local manufacturing know-how. If we were to ever find ourselves in a similar situation, we will be able to produce key commodity medicines here in Australia,” said Mr Thulborne.
Noumed is an Australian Over the Counter (OTC) & Prescription (RX) pharmaceutical company that currently supplies customers in Australia and New Zealand with proprietary products via its Adelaide distribution hub. The company’s decision to shift its manufacturing focus to Australia will boost local knowledge, collaboration and employment pathways.
“We have a global footprint of contract manufacturing, and while we can’t name our clients contractually, they include many recognizable brands you would see on pharmacy and supermarket shelves.
“By coming back into Australia, current and future clients can have the comfort that many of their products are being made in South Australia. This means a shorter lead time to their shelves and a supplier that can react quickly to their individual needs. It will give them an unmatched competitive advantage.
“The project will also boost local employment, creating around 250 jobs during construction and 180 positions for future employees across pharmacy, science, engineering and logistics. It will also allow us to build partnerships with local research and educational institutions,” said Mr Thulborne.
Noumed acknowledges Terre Property Partners, TMX and FDC for their contribution to the design and development of this project.

Must Read

2024 Asthma and Airways Career Development Fellowship

0
The National Asthma Council has announced that Associate Professor Rachel Peters has received the 2024 Asthma and Airways Career Development Fellowship, jointly funded by...